Oppenheimer analyst Leah R. Cann maintained a Buy rating on Epizyme (NASDAQ: EPZM) today and set a price target of $25. The company’s shares opened today at $15.80.
Cann said:
“The interim data presented today for Tazemetostat in follicular lymphoma continue to be impressive, especially in the EZH2-mutant population. With an overall response rate of 71% and complete response rate of 11%, along with mPFS of 49 weeks, these data compare very favorably to single-agents used in this setting. In the reference data for this setting, detailed on pages 40-41 in our report Edition, response rates, mPFS and duration on therapy were all lower than those presented for today for tazemetostat. The data released today support Tazemetostat’s potential in follicular lymphoma and supports our expectations for launch.”
According to TipRanks.com, Cann is a 5-star analyst with an average return of 23.8% and a 61.5% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.
Currently, the analyst consensus on Epizyme is Strong Buy and the average price target is $24.38, representing a 54.3% upside.
In a report issued on June 11, Roth Capital also maintained a Buy rating on the stock with a $26 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $21.40 and a one-year low of $11.15. Currently, Epizyme has an average volume of 416.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Develops therapeutics for the treatment of patients with genetically defined cancers
